Pharmaids Pharmaceuticals Limited (BOM:524572)
India · Delayed Price · Currency is INR 32.28
+3.54 (12.32%)
At close: Jun 17, 2026
Pharmaids Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 278.82 | 194.47 | 151.12 | - | 39.39 |
Other Revenue | - | 0.66 | 1.88 | - | - |
| 278.82 | 195.14 | 153 | - | 39.39 | |
Revenue Growth (YoY) | 42.89% | 27.54% | - | - | -53.93% |
Cost of Revenue | 171.53 | 132.37 | 125.11 | 9.04 | 35.71 |
Gross Profit | 107.3 | 62.76 | 27.89 | -9.04 | 3.68 |
Selling, General & Admin | 133.77 | 144.25 | 97.01 | 13.06 | 0.67 |
Other Operating Expenses | 108.9 | 45.2 | 51.95 | 76.81 | 1.63 |
Operating Expenses | 262.95 | 213.85 | 166.22 | 90.04 | 2.4 |
Operating Income | -155.65 | -151.09 | -138.32 | -99.08 | 1.28 |
Interest Expense | -34.92 | -20.07 | -15.42 | - | - |
Interest & Investment Income | - | 0.29 | 0.28 | - | - |
Currency Exchange Gain (Loss) | - | -0.14 | -0.45 | - | - |
Other Non Operating Income (Expenses) | 2.89 | -0.8 | 6.2 | -0 | 0.12 |
EBT Excluding Unusual Items | -187.67 | -171.81 | -147.71 | -99.08 | 1.4 |
Gain (Loss) on Sale of Investments | - | - | -0.32 | - | - |
Other Unusual Items | 24.65 | -0.98 | -8.18 | - | - |
Pretax Income | -163.03 | -172.79 | -156.21 | -99.08 | 1.4 |
Income Tax Expense | -47.31 | -37.74 | -37.78 | -23.52 | -0.05 |
Earnings From Continuing Operations | -115.72 | -135.05 | -118.43 | -75.56 | 1.45 |
Minority Interest in Earnings | -1.45 | 27.29 | 38.75 | - | - |
Net Income | -117.17 | -107.77 | -79.68 | -75.56 | 1.45 |
Net Income to Common | -117.17 | -107.77 | -79.68 | -75.56 | 1.45 |
Net Income Growth | - | - | - | - | 55.55% |
Shares Outstanding (Basic) | 35 | 35 | 23 | 13 | 10 |
Shares Outstanding (Diluted) | 35 | 35 | 23 | 13 | 10 |
Shares Change (YoY) | 0.37% | 55.24% | 76.16% | 25.07% | - |
EPS (Basic) | -3.31 | -3.06 | -3.51 | -5.86 | 0.14 |
EPS (Diluted) | -3.31 | -3.06 | -3.51 | -5.86 | 0.14 |
EPS Growth | - | - | - | - | 55.56% |
Free Cash Flow | -85.29 | -264.72 | -334.82 | -56.92 | -2.59 |
Free Cash Flow Per Share | -2.41 | -7.51 | -14.74 | -4.41 | -0.25 |
Gross Margin | 38.48% | 32.16% | 18.23% | - | 9.34% |
Operating Margin | -55.82% | -77.43% | -90.41% | - | 3.25% |
Profit Margin | -42.02% | -55.23% | -52.08% | - | 3.69% |
Free Cash Flow Margin | -30.59% | -135.66% | -218.84% | - | -6.58% |
EBITDA | -135.38 | -128.03 | -121.07 | -98.91 | 1.36 |
EBITDA Margin | -48.55% | -65.61% | -79.13% | - | 3.46% |
D&A For EBITDA | 20.27 | 23.06 | 17.25 | 0.17 | 0.08 |
EBIT | -155.65 | -151.09 | -138.32 | -99.08 | 1.28 |
EBIT Margin | -55.82% | -77.43% | -90.41% | - | 3.25% |
Revenue as Reported | 281.71 | 195.51 | 159.9 | - | 39.54 |
Advertising Expenses | - | 1.34 | 0.15 | 0 | 0.11 |